Novo Nordisk Will Eat Itself In Obesity
Executive Summary
The Danish diabetes specialist is forging ahead with pivotal trials for its latest GLP-1 offering semaglutide in obesity after highly impressive Phase II efficacy data, but is likely to take the biggest market share from its own product, Saxenda.
You may also be interested in...
Novo Nordisk's Great Hope Semaglutide Shines In Ph II Obesity Study
Highly positive top-line weight loss results for Novo Nordisk's new GLP-1 agonist semaglutide are propelling it into Phase III trials next year for the notoriously tricky indication. The product is currently under review for type 2 diabetes.
Nine Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are nine (plus a few extras) that have caught attention for one reason or another, e.g., for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.
10 Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are ten (plus a few extras) that have caught Scrip’s eye for one reason or another, eg, for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.